Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer

Conditions

• Adult Hepatocellular Carcinoma
• Advanced Adult Hepatocellular Carcinoma
• Endometrial Serous Adenocarcinoma
• Localized Non-Resectable Adult Liver Carcinoma
• Lung Carcinoid Tumor
• Malignant Pancreatic Gastrinoma
• Malignant Pancreatic Glucagonoma
• Malignant Pancreatic Insulinoma
• Malignant Pancreatic Somatostatinoma
• Metastatic Digestive System Neuroendocrine Tumor G1
• Ovarian Carcinosarcoma
• Ovarian Endometrioid Adenocarcinoma
• Ovarian Seromucinous Carcinoma
• Ovarian Serous Surface Papillary Adenocarcinoma
• Pancreatic Alpha Cell Adenoma
• Pancreatic Beta Cell Adenoma
• Pancreatic Delta Cell Adenoma
• Pancreatic G-Cell Adenoma
• Pancreatic Polypeptide Tumor
• Recurrent Adult Liver Carcinoma
• Recurrent Digestive System Neuroendocrine Tumor G1
• Recurrent Fallopian Tube Carcinoma
• Recurrent Ovarian Carcinoma
• Recurrent Pancreatic Neuroendocrine Carcinoma
• Recurrent Primary Peritoneal Carcinoma
• Recurrent Uterine Corpus Carcinoma
• Regional Digestive System Neuroendocrine Tumor G1
• Stage IIIA Fallopian Tube Cancer
• Stage IIIA Ovarian Cancer
• Stage IIIA Primary Peritoneal Cancer
• Stage IIIA Uterine Corpus Cancer
• Stage IIIB Fallopian Tube Cancer
• Stage IIIB Ovarian Cancer
• Stage IIIB Primary Peritoneal Cancer
• Stage IIIB Uterine Corpus Cancer
• Stage IIIC Fallopian Tube Cancer
• Stage IIIC Ovarian Cancer
• Stage IIIC Primary Peritoneal Cancer
• Stage IIIC Uterine Corpus Cancer
• Stage IV Fallopian Tube Cancer
• Stage IV Ovarian Cancer
• Stage IV Primary Peritoneal Cancer
• Stage IVA Uterine Corpus Cancer
• Stage IVB Uterine Corpus Cancer
• Uterine Carcinosarcoma

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Bevacizumab — BIOLOGICAL
  Given IV
• Temsirolimus — DRUG
  Given IV

Study Details

This phase II trial studies how well temsirolimus and bevacizumab work in treating patients with advanced endometrial, ovarian, liver, carcinoid, or islet cell cancer. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of cancer by blocking blood flow to the tumor. Giving temsirolimus together with bevacizumab may kill more tumor cells.

Key Dates

First listed

Nov 9, 2009

Start date

Sep 8, 2009

Status verified

Jan 2019

Primary completion

Mar 13, 2017

Completion

Mar 13, 2017

Study Design

Enrollment

252 participants (actual)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Experimental: Treatment (temsirolimus, bevacizumab)
  Patients receive temsirolimus IV on days 1, 8, 15, and 22, and bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Primary Outcome Measure

Progression Free Survival Rate [ Time Frame: 6 months ]

Locations (57)

Find similar trials in Scottsdale, AZ

Related Studies

• Study of Tumor Tissue Samples From Patients Who Have Undergone Surgery for Advanced Stage III or Stage IV Ovarian Epithelial Cancer
  Recruiting · Gynecologic Oncology Group · Philadelphia, Pennsylvania
• Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer
  PHASE3 · Recruiting · University of Utah · Palo Alto, California
• Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF
  PHASE1 · Recruiting · M.D. Anderson Cancer Center · Houston, Texas
• Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers
  PHASE1 · Recruiting · M.D. Anderson Cancer Center · Baltimore, Maryland